logo
In Honor Of World Asteroid Day, A Short History Of Planetary Defense

In Honor Of World Asteroid Day, A Short History Of Planetary Defense

Forbes30-06-2025
World Asteroid Day started with a real bang.
An artist's illustration of asteroid Bennu
On June 30, 1908, an asteroid about 65 meters wide collided with Earth's atmosphere and exploded several miles above Siberia; the force of the blast flattened and burned millions of trees over an area of more than 2,000 square kilometers. Today, the anniversary of the Tunguska blast has become World Asteroid Day: a science holiday co-founded by a rock music legend and an Apollo astronaut.
In 2015, Apollo 9 lunar module pilot Rusty Schweickart helped launch World Asteroid Day with astrophysicist and Queen guitarist Brian May. The United Nations officially recognized the event a year later in 2016. Earlier this month, Arizona senator Mark Kelly – also a former astronaut – introduced a Senate resolution that, if passed, would officially recognize June 30 as World Asteroid Day in the U.S.
I spoke with Kevin Schindler, resident historian at Lowell Observatory in Arizona, about the origins of World Asteroid Day, the history of planetary defense, and what asteroids can reveal about the history of our Solar System.
Discovering the Danger from Outer Space
Around 200 years ago, in the 1830s, geologists began to study fossils and figure out that several mass extinctions had wiped out whole ecosystems of species on Earth in the distant past.
'In recent decades, they realized that those weren't necessarily caused by something on Earth, but by something impacting from space – like the Cretaceous Tertiary boundary,' says Schindler.
An artist's impression of a giant meteor impact.
In the 1960s, geologist Walter Alvarez discovered a thin layer of black clay in rocks around the world. Below the black line, the rocks were rich in fossils; above it, they were nearly barren. The same layer of black clay showed up all around in the world: in rock outcroppings in Italy and New Zealand, and in samples from the floor of the Pacific Ocean. And it clearly marked a deadly before-and-after moment in Earth's history – one that happened around 66 million years ago.
Alvarez suspected that the black clay was something alien; it contained bizarrely large amounts of an element called iridium, which is vanishingly rare here on Earth but more common in asteroids. He began to realize that an asteroid or comet may have slammed into our planet 66 million years ago, kicking off a mass extinction and scattering iridium-rich black dust over the planet like a burial shroud.
The pieces came together in 1978 when geophysicists Glen Penfield and Antonio Camargo discovered the outline of a crater hundreds of kilometers wide at the edge of Mexico's Yucatan Peninsula. Its center lies at the bottom of the Gulf of Mexico. Penfield and Camargo named the crater for one of the communities that now lies within its boundaries: Chicxulub Pueblo.
Other craters – smaller but still impressive – also make it obvious that our planet has had more than a few run-ins with meteors during its long history.
'And while there's not as much debris floating around in our Solar System as when it was newly-formed, there's still stuff out there,' says Schindler. 'And it's inevitable that at some point that stuff will come back and get us again.'
NASA's Asteroid Watch tracks known asteroids and comets in the Solar System, while observatories ... More like Lowell scan the skies for more.
From Deep Impact to DART
So we've known almost 60 years that asteroids and comets could threaten life on Earth.
'In the 1980s and 1990s, there was a search to look for bodies that specifically could impact Earth,' says Schindler. 'Phase one of all this started with, 'okay, let's look for these bodies that could hit us,' and then a couple decades later is when we got to phase two, 'what can we do about it if we do find these things?''
Strangely enough, it was a pair of high-budget, low-scientific-accuracy Hollywood blockbusters that really brought planetary defense to public attention, according to Schindler. The summer of 1998 featured not just one but two movies about humanity trying to save itself from extinction by blowing up an incoming chunk of space rock. In Armageddon, a wildly-improbable effort by a team of offshore drillers saves Earth from an asteroid impact; in Deep Impact, a similarly-improbable effort fails to save Earth from a comet (so the summer ends in a cinematic tie).
Two men in a space suit using a piece of machinery in a scene from the film 'Deep Impact', 1998. ... More (Photo by)
'The good thing about those movies is that, even though they're not scientifically accurate in every way, they certainly built awareness enough to where lawmakers said, you know, we should put some money aside to study this stuff more,' says Schindler. 'Hollywood, in some ways, has helped the cause to learn more.'
And, as science fiction often does, Deep Impact and Armageddon provided thought experiments (albeit not super-accurate ones, to put it mildly) for the ideas that would eventually become actual efforts at planetary defense. According to Schindler, theoretical ideas about whether we could destroy an incoming meteor eventually shifted to ideas about just nudging the deadly object off-course.
'This is just something that's really been developed in the last decade or so and – I wouldn't say culminated, but really became well-known with the mission that went up to deflect the moon of an asteroid to see if it was possible,' says Schindler.
Artist rendering of the NASA Double Asteroid Redirection Test (DART) space probe approaching the ... More asteroid Didymos and its minor-planet-moon Dimorphos. The DART spacecraft aims to collide with Dimorphos in autumn 2022 in order to study the effect of an impact with near-Earth objects. Created on September 13, 2021. (Illustration by Nicholas Forder/Future Publishing via Getty Images)
That mission was NASA's Double Asteroid Redirection Test, or DART, in which an intrepid little spacecraft flew 7 million miles to crash into the asteroid Dimorphos and knock it off-course. Dimorphos is actually a mini-moon that orbits another, larger asteroid called Didymos. Astronomers at Lowell carefully measured Dimorphos's orbital path around its parent asteroid before and after the impact – and they saw evidence that DART had succeeded in knocking Dimorphos into a different orbit.
It's a long, long way from deflecting one tiny asteroid moonlet onto a different path around its parent asteroid to deflecting something the size of the Chicxulub impactor – or even Tunguska – as it's barreling toward Earth. But the consensus seems to be that DART was a good start.
'The biggest thing, I think, was that it is possible. This was a very controlled initial step,' says Schindler. 'This was certainly promising enough that we should keep doing these tests in different sizes of body and different compositions, because depending on what it's made of, a body might react differently to something impacting it.'
Fossils of the Early Solar System
This illustration depicts the 140-mile-wide (226-kilometer-wide) asteroid Psyche, which lies in the ... More main asteroid belt between Mars and Jupiter.
Meanwhile, Schindler and World Asteroid Day also want the public to know that asteroids are more than potential threats: they're an orbiting treasure trove of information about the history of our Solar System and even the origins of life.
Most asteroids are chunks of rock that coalesced early in our Solar System's history but never grew massive enough to become planets; they're like the seeds of planets that might have been. Others are the debris left behind by collisions between objects in those chaotic early days of the Solar System, when planets were forming and gas giants migrated, scattering lesser objects in their wake.
'They tell us what the early composition was and what a chaotic time it was in the early part of our Solar System,' says Schindler.
Those clues are written not just in the chemical and physical makeup of asteroids, but in their orbital paths around the Sun. By studying and modelling how those paths have changed over the years, scientists can reconstruct how asteroids and planets may have interacted. The orbits of modern asteroids are like the 'footprints' of planet formation, migrating gas giants, and long-ago collisions.
Today, NASA's Lucy mission is exploring the asteroid belt, getting up close and personal with several of these objects. Meanwhile, NASA's OSIRIS-APEX mission is on its way to study the asteroid Apophis, which will pass close (but not too close!) to Earth in 2029.
The surface of asteroid Bennu, as seen by OSIRIS-REX in late 2020, is strewn with boulders.
'And now we are studying planetary systems around other stars. Better understanding our Solar System, we can now look at others and see how typical we are,' says Schindler. 'You don't know that without knowing your own Solar System pretty well, so it really has helped us to learn about, sort of, our heritage, I guess.'
World Asteroid Day
World Asteroid Day aims to tie all of those things together, promoting awareness of planetary defense but also of the immense scientific value – and maybe monetary value, eventually – of asteroids.
At Lowell Observatory, that awareness is hard to escape; the observatory stands just an hour's drive from Meteor Crater – which is exactly what the name suggests, a 213-meter-deep, 1200-meter-wide crater where an object about the size of a Boeing 747 slammed into the desert floor around 50,000 years ago.
'The proximity of Lowell Observatory, where we're studying bodies in space, and Meteor crater, where we've seen the result of one of those bodies hitting Earth – how convenient is that? We're looking at both ends of it, from when it's still up in space to the final product if something like this hits.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

Yahoo

timean hour ago

  • Yahoo

ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102
Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

Yahoo

time2 hours ago

  • Yahoo

Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102

Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the . On April 14, Verve Therapeutics, Inc. (NASDAQ:VERV) reported results from its Heart-2 Phase 1b trial for VERVE-102. The trial focused on treating people with heterozygous familial hypercholesterolemia or early heart disease. Such patients need to lower their LDL cholesterol levels for a long time. Management noted that 14 participants received VERVE-102 at different doses, and the treatment was marked safe as there were no serious side effects connected to the drug and no important lab problems were seen. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. The results showed that a single infusion of VERVE-102 reduced a key blood protein and significantly dropped LDL cholesterol. The reduction was dependent on the dose, with a mean reduction of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort. Management believes that these results are promising, as a single dose can offer long-lasting reduction in LDL cholesterol. Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company developing genetic medicines for cardiovascular disease. Their treatments aim to provide long-lasting effects with a single gene-editing therapy instead of ongoing medication. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

AI summit coming to Pittsburgh later this year will be headlined by Gov. Shapiro, Sen. McCormick
AI summit coming to Pittsburgh later this year will be headlined by Gov. Shapiro, Sen. McCormick

CBS News

time2 hours ago

  • CBS News

AI summit coming to Pittsburgh later this year will be headlined by Gov. Shapiro, Sen. McCormick

Governor Josh Shapiro and Pennsylvania Senator Dave McCormick will be headlining an AI summit in Pittsburgh later this year. AI Horizons 2025 will be held on September 11 and September 12 in the city's Bakery Square and is expected to "shine a spotlight on systems that interact with the real world through robotics, autonomy, simulation, and embedded AI." "From steel to AI, Pittsburgh has always built what the world needs next," said Joanna Doven, Executive Director of the AI Strike Team. "With deep industrial roots, top-tier research institutions, and bipartisan leadership, we are positioned to become the Physical AI capital of the world. AI Horizons is where that vision becomes action." The event will get underway on September 10 when more than $100,000 in prize money will be given out to startups in a competition. In addition to Gov. Shapiro and Sen. McCormick, executives from the tech community including Gecko Robotics and Skild AI are expected to be in attendance. The September summit announcement comes on the heels of the Inaugural Pennsylvania Energy and Innovation Summit at Carnegie Mellon University where President Trump and many leaders of the country's largest technology and energy companies announced more than $90 billion in new investments from private companies in Pennsylvania. "We don't just research AI here—we build it, deploy it, and power it," Doven said. "This is the next generation of industry, and just like we led with steel, we can lead again with AI." The full agenda and list of speakers is expected to be released early next month.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store